XOMA Royalty Declares Quarterly Preferred Stock Dividends

Rhea-AI Summary

XOMA Royalty (Nasdaq: XOMA) declared quarterly cash dividends for its preferred shares on Dec 22, 2025. The Board authorized a dividend of $0.53906 per share for the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) and $0.52344 per depositary share for depositary shares representing 1/1000 of the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO).

Both preferred dividends are payable on or about Jan 15, 2026 to holders of record at the close of business on Jan 2, 2026.

Positive

• Declared cash dividend of $0.53906 for Series A preferred
• Declared cash dividend of $0.52344 per Series B depositary share
• Payment scheduled for Jan 15, 2026 with record date Jan 2, 2026

Negative

• None.

EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock:

Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.

Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.

The preferred dividends will be paid on or about January 15, 2026, to respective holders of record at the close of business on January 2, 2026.

About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the sellers receive non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about XOMA Royalty and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.  Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.

As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO^® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY^® [coagulation factor IX (recombinant)], and DSUVIA^® (sufentanil sublingual tablet).  All other assets in the milestone and royalty portfolio are investigational compounds.  Efficacy and safety have not been established.  There is no guarantee that any of the investigational compounds will become commercially available.

Investor Contact         Juliane Snowden         XOMA Royalty Corporation         +1 646-438-9754         juliane.snowden@xoma.com

Media Contact Kathy Vincent KV Consulting & Management kathy@kathyvincent.com

FAQ

What dividend did XOMA Royalty (XOMA) declare for Series A preferred on Dec 22, 2025?

The Board declared a cash dividend of $0.53906 per share for the 8.625% Series A preferred.

How much is the XOMA Royalty Series B depositary share dividend and what does one depositary share represent?

The dividend is $0.52344 per depositary share; each depositary share represents 1/1000 of a share of the 8.375% Series B preferred.

When will XOMA Royalty preferred dividends be paid and who is eligible?

Dividends are payable on or about Jan 15, 2026 to holders of record at the close of business on Jan 2, 2026.

What are the Nasdaq ticker symbols for XOMA Royalty preferred shares declared Dec 22, 2025?

Series A preferred trades as XOMAP and Series B depositary shares trade as XOMAO.

Are these preferred dividends cumulative for XOMA Royalty (XOMA)?

Yes; both declared instruments are described as cumulative perpetual preferred in the announcement.